We use cookies to improve your website experience. To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy. By continuing to use the website, you consent to our use of cookies.
In Vivo is part of Pharma Intelligence UK Limited
This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.
This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183
Grail plans Series B round in excess of $1bn; closes initial tranches
21 Nov 2017
Executive Summary
Molecular diagnostics firm Grail Inc. (founded by Illumina last year) announced plans to raise at least $1bn through a Series B round from undisclosed private and strategic investors. The round is expected to close by the end of the first quarter. Proceeds will support development of the company's first blood-based cancer diagnostics, and will also be used to repurchase a portion of Illumina's stake. Following the transaction, Illumina will only own less than 20%, and instead of being a division, Grail will become one of Illumina's largest sequencing customers.
Deal Industry
Biotechnology
In Vitro Diagnostics
In Vitro Diagnostics
Molecular Diagnostics & Genetic Testing
Deal Status
Final
Deal Type
Financing
Venture Financing
Already a Biomedtracker subscriber?You have access to the full deal record through your subscription
Want to become a subscriber?Subscribers get more deal details, updates, deal financials and deal products.Questions?